Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab as neoadjuvant therapy in muscle-invasive bladder cancer
2017-002758-35Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) (4 arms), sponsored by Institut Jules Bordet. Primary endpoints: Pathologic complete response rate and Safety and tolerability. Started Apr 2018; status: completed.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2017-002758-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002758-35.